FDAnews
www.fdanews.com/articles/206947-luminexs-nxtag-gastrointestinal-pathogen-panel-gets-ce-ivd-mark

Luminex’s NxTAG Gastrointestinal Pathogen Panel Gets CE-IVD Mark

March 14, 2022

Austin, Tex.-based Luminex’s NxTAG gastrointestinal pathogen in vitro diagnostic panel has received CE-IVD mark certification.

The NxTAG technology uses a proprietary universal tag system that allows easy development and optimization of nucleic acid assays. The TAG portion of the name represents the proprietary sequences designed by Luminex for nucleic acid applications.

The polymerase chain-reaction test, which can detect 16 bacterial, viral and parasitic targets from human stool specimens, is indicated for individuals with signs and symptoms of infectious colitis or gastroenteritis.

Luminex is a subsidiary of DiaSorin, which is headquartered in Saluggia, Italy.

View today's stories